Enanta Pharmaceuticals’ (ENTA) Buy Rating Reaffirmed at HC Wainwright

Enanta Pharmaceuticals (NASDAQ:ENTA)‘s stock had its “buy” rating reaffirmed by equities researchers at HC Wainwright in a research report issued on Wednesday, Benzinga reports. They currently have a $20.00 target price on the biotechnology company’s stock. HC Wainwright’s price objective would indicate a potential upside of 61.03% from the stock’s current price.

Other equities research analysts also recently issued research reports about the company. Wall Street Zen downgraded Enanta Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, August 22nd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Enanta Pharmaceuticals in a research note on Friday, July 17th. Five research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, Enanta Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $21.00.

Enanta Pharmaceuticals Price Performance

NASDAQ ENTA opened at $12.42 on Wednesday. Enanta Pharmaceuticals has a 12 month low of $7.05 and a 12 month high of $17.15. The company has a 50-day moving average of $13.24 and a 200-day moving average of $13.35. The company has a market cap of $361.67 million, a P/E ratio of -5.15 and a beta of 0.93.

Enanta Pharmaceuticals (NASDAQ:ENTA) last posted its quarterly earnings results on Monday, August 10th. The biotechnology company reported ($0.67) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.16). The company had revenue of $14.36 million for the quarter, compared to analysts’ expectations of $16.76 million. Enanta Pharmaceuticals had a negative return on equity of 61.84% and a negative net margin of 96.89%. As a group, equities research analysts anticipate that Enanta Pharmaceuticals will post -2.36 EPS for the current year.

Institutional Trading of Enanta Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the business. Jupiter Topco LLC purchased a new position in Enanta Pharmaceuticals in the second quarter valued at about $53,252,000. Janus Henderson Group PLC boosted its position in shares of Enanta Pharmaceuticals by 1.5% in the first quarter. Janus Henderson Group PLC now owns 3,784,055 shares of the biotechnology company’s stock worth $47,717,000 after buying an additional 54,396 shares during the period. BlackRock Inc. purchased a new stake in shares of Enanta Pharmaceuticals in the second quarter worth about $47,304,000. ADAR1 Capital Management LLC acquired a new stake in shares of Enanta Pharmaceuticals in the second quarter valued at about $19,603,000. Finally, Spruce Street Capital LP acquired a new stake in shares of Enanta Pharmaceuticals in the second quarter valued at about $15,873,698. 94.99% of the stock is owned by hedge funds and other institutional investors.

Enanta Pharmaceuticals Company Profile

Enanta Pharmaceuticals, Inc is a biotechnology company focused on discovering and developing small-molecule therapies for viral infections and other diseases. The company’s research has primarily centered on antiviral medicines, including treatments for respiratory syncytial virus (RSV), hepatitis B, and other infectious diseases.

Enanta is best known for its role in the development of glecaprevir, a protease inhibitor used with pibrentasvir in AbbVie’s Mavyret (also marketed as Maviret) treatment for chronic hepatitis C virus infection.